Donanemab for Alzheimer’s Disease: A Systematic Review of Clinical Trials
Amyloid-β (Aβ) plaques and aggregated tau are two core mechanisms that contribute to the clinical deterioration of Alzheimer’s disease (AD). Recently, targeted-Aβ plaque reduction immunotherapies have been explored for their efficacy and safety as AD treatment. This systematic review critically revi...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Healthcare |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9032/11/1/32 |
| _version_ | 1797625751804051456 |
|---|---|
| author | Areeba Rashad Atta Rasool Muhammad Shaheryar Azza Sarfraz Zouina Sarfraz Karla Robles-Velasco Ivan Cherrez-Ojeda |
| author_facet | Areeba Rashad Atta Rasool Muhammad Shaheryar Azza Sarfraz Zouina Sarfraz Karla Robles-Velasco Ivan Cherrez-Ojeda |
| author_sort | Areeba Rashad |
| collection | DOAJ |
| description | Amyloid-β (Aβ) plaques and aggregated tau are two core mechanisms that contribute to the clinical deterioration of Alzheimer’s disease (AD). Recently, targeted-Aβ plaque reduction immunotherapies have been explored for their efficacy and safety as AD treatment. This systematic review critically reviews the latest evidence of Donanemab, a humanized antibody that targets the reduction in Aβ plaques, in AD patients. Comprehensive systematic search was conducted across PubMed/MEDLINE, CINAHL Plus, Web of Science, Cochrane, and Scopus. This study adhered to PRISMA Statement 2020 guidelines. Adult patients with Alzheimer’s disease being intervened with Donanemab compared to placebo or standard of care in the clinical trial setting were included. A total of 396 patients across four studies received either Donanemab or a placebo (228 and 168 participants, respectively). The Aβ-plaque reduction was found to be dependent upon baseline levels, such that lower baseline levels had complete amyloid clearance (<24.1 Centiloids). There was a slowing of overall tau levels accumulation as well as relatively reduced functional and cognitive decline noted on the Integrated Alzheimer’s Disease Rating Scale by 32% in the Donanemab arm. The safety of Donanemab was established with key adverse events related to Amyloid-Related Imaging Abnormalities (ARIA), ranging between 26.1 and 30.5% across the trials. There is preliminary support for delayed cognitive and functional decline with Donanemab among patients with mild-to-moderate AD. It remains unclear whether Donenameb extends therapeutic benefits that can modify and improve the clinical status of AD patients. Further trials can explore the interplay between Aβ-plaque reduction and toxic tau levels to derive meaningful clinical benefits in AD patients suffering from cognitive impairment. |
| first_indexed | 2024-03-11T10:00:47Z |
| format | Article |
| id | doaj.art-56ff5dd8704b48e9bda2a9c763a8aa9c |
| institution | Directory Open Access Journal |
| issn | 2227-9032 |
| language | English |
| last_indexed | 2024-03-11T10:00:47Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Healthcare |
| spelling | doaj.art-56ff5dd8704b48e9bda2a9c763a8aa9c2023-11-16T15:24:36ZengMDPI AGHealthcare2227-90322022-12-011113210.3390/healthcare11010032Donanemab for Alzheimer’s Disease: A Systematic Review of Clinical TrialsAreeba Rashad0Atta Rasool1Muhammad Shaheryar2Azza Sarfraz3Zouina Sarfraz4Karla Robles-Velasco5Ivan Cherrez-Ojeda6Department of Research and Publications, Fatima Jinnah Medical University, Lahore 54000, PakistanDepartment of Research, Services Institute of Medical Sciences, Lahore 54000, PakistanDepartment of Research, Rawal Institute of Health Sciences, Islamabad 45550, PakistanDepartment of Pediatrics and Child Health, The Aga Khan University, Karachi 74800, PakistanDepartment of Research and Publications, Fatima Jinnah Medical University, Lahore 54000, PakistanDepartment of Allergy, Immunology & Pulmonary Medicine, Universidad Espíritu Santo, Samborondón 092301, EcuadorDepartment of Allergy, Immunology & Pulmonary Medicine, Universidad Espíritu Santo, Samborondón 092301, EcuadorAmyloid-β (Aβ) plaques and aggregated tau are two core mechanisms that contribute to the clinical deterioration of Alzheimer’s disease (AD). Recently, targeted-Aβ plaque reduction immunotherapies have been explored for their efficacy and safety as AD treatment. This systematic review critically reviews the latest evidence of Donanemab, a humanized antibody that targets the reduction in Aβ plaques, in AD patients. Comprehensive systematic search was conducted across PubMed/MEDLINE, CINAHL Plus, Web of Science, Cochrane, and Scopus. This study adhered to PRISMA Statement 2020 guidelines. Adult patients with Alzheimer’s disease being intervened with Donanemab compared to placebo or standard of care in the clinical trial setting were included. A total of 396 patients across four studies received either Donanemab or a placebo (228 and 168 participants, respectively). The Aβ-plaque reduction was found to be dependent upon baseline levels, such that lower baseline levels had complete amyloid clearance (<24.1 Centiloids). There was a slowing of overall tau levels accumulation as well as relatively reduced functional and cognitive decline noted on the Integrated Alzheimer’s Disease Rating Scale by 32% in the Donanemab arm. The safety of Donanemab was established with key adverse events related to Amyloid-Related Imaging Abnormalities (ARIA), ranging between 26.1 and 30.5% across the trials. There is preliminary support for delayed cognitive and functional decline with Donanemab among patients with mild-to-moderate AD. It remains unclear whether Donenameb extends therapeutic benefits that can modify and improve the clinical status of AD patients. Further trials can explore the interplay between Aβ-plaque reduction and toxic tau levels to derive meaningful clinical benefits in AD patients suffering from cognitive impairment.https://www.mdpi.com/2227-9032/11/1/32Alzheimer’s diseasedonanemabplaquecognitionelderly care |
| spellingShingle | Areeba Rashad Atta Rasool Muhammad Shaheryar Azza Sarfraz Zouina Sarfraz Karla Robles-Velasco Ivan Cherrez-Ojeda Donanemab for Alzheimer’s Disease: A Systematic Review of Clinical Trials Healthcare Alzheimer’s disease donanemab plaque cognition elderly care |
| title | Donanemab for Alzheimer’s Disease: A Systematic Review of Clinical Trials |
| title_full | Donanemab for Alzheimer’s Disease: A Systematic Review of Clinical Trials |
| title_fullStr | Donanemab for Alzheimer’s Disease: A Systematic Review of Clinical Trials |
| title_full_unstemmed | Donanemab for Alzheimer’s Disease: A Systematic Review of Clinical Trials |
| title_short | Donanemab for Alzheimer’s Disease: A Systematic Review of Clinical Trials |
| title_sort | donanemab for alzheimer s disease a systematic review of clinical trials |
| topic | Alzheimer’s disease donanemab plaque cognition elderly care |
| url | https://www.mdpi.com/2227-9032/11/1/32 |
| work_keys_str_mv | AT areebarashad donanemabforalzheimersdiseaseasystematicreviewofclinicaltrials AT attarasool donanemabforalzheimersdiseaseasystematicreviewofclinicaltrials AT muhammadshaheryar donanemabforalzheimersdiseaseasystematicreviewofclinicaltrials AT azzasarfraz donanemabforalzheimersdiseaseasystematicreviewofclinicaltrials AT zouinasarfraz donanemabforalzheimersdiseaseasystematicreviewofclinicaltrials AT karlaroblesvelasco donanemabforalzheimersdiseaseasystematicreviewofclinicaltrials AT ivancherrezojeda donanemabforalzheimersdiseaseasystematicreviewofclinicaltrials |